ABBV Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?

AbbVie’s 2026 outlook leans positive despite Humira LOE: management expects combined Skyrizi + Rinvoq sales of >$31B, up >20% in 2026 (with $14.6B in 1H) to offset Humira’s ~38.2% H1 2026 decline. The company also highlights neuroscience growth (Q2 neuroscience sales +19.8% to $3.23B) and expects total revenue to rise ~10% in 2026, with high single-digit growth through 2029. Near-term headwinds include low single-digit pricing pressure for Skyrizi/Rinvoq, aesthetics macro softness, and oncology slowing (Q2 oncology -2.4%); meanwhile, 2026 earnings estimates edged down ($14.28 to $14.05) over 60 days.

Analysis

ABBV is in the awkward phase where the market is willing to pay for de-risked replacement growth, but not for a clean re-rating. The key mechanism is mix: immunology and neuroscience are now doing the heavy lifting, yet pricing pressure and acquired IPR&D charges cap near-term margin expansion, so the stock can grind higher without multiple expansion. That makes the current setup more suitable for owning on dips than chasing after strength.

Competitive dynamics are more interesting in immunology than the headline suggests. JNJ’s oral psoriasis entry is less about immediately dislodging share and more about forcing payer and physician behavior toward step-therapy scrutiny, which can slow conversion and compress Skyrizi velocity over the next 2-3 quarters. The offset is that AbbVie’s broader IBD and dermatology stack gives it more shots on goal than a single-product challenger, so the real loser may be smaller biotech names in adjacent inflammatory indications that lose the “best-in-class” narrative premium.

The bigger risk is that consensus is extrapolating 2026 revenue strength into EPS strength too quickly. With 2026 estimates already drifting down, a modest miss on Skyrizi/Rinvoq uptake or a delay in tavapadon would hit sentiment harder than the revenue line implies; conversely, approval/data catalysts over the next 1-3 months can keep the tape supported. Structurally, if arthritis/IBD share gains persist and aesthetics stabilizes, ABBV can defend a premium multiple, but absent that, the stock is vulnerable to mean reversion because it already trades above its own long-run average.

Contrarian view: the market may be underappreciating how much of the stock’s resilience is already in the price. The technical trend is favorable, but fundamentals still need to prove that the post-Humira portfolio can sustain high-single-digit growth without needing increasingly expensive M&A. If the next two quarters show any deceleration in Rx share or weaker pricing, the current valuation leaves limited room for disappointment.

Key Decisions for Investors

• Long ABBV on 3-6 month pullbacks, not strength: use weakness toward the 50-day moving average as an entry for a defensive growth-plus-yield exposure; thesis breaks if 2026 EPS trends below current consensus or Skyrizi/Rinvoq growth slows materially in the next two quarters.
• Pair trade: long ABBV / short JNJ for 1-3 months if you believe oral psoriasis launch excitement is over-earning the competitive impact; risk/reward improves if channel checks show limited payer conversion to JNJ’s pill.
• Buy ABBV only on confirmation, not anticipation, around the Q3 2026 tavapadon FDA decision and hidradenitis data: these are the cleanest catalysts for incremental multiple support; exit if the decision slips or launch uptake disappoints.
• Hedge AbbVie exposure with a short in XBI if you want to isolate large-cap immunology durability versus broader biotech beta; ABBV should be more insulated than the index if rates or risk appetite roll over.
• Avoid chasing upside in front of the next quarter if the stock is already extended above both major moving averages; the cleaner trade may be selling upside calls against a core long because the valuation premium is now anchored to execution rather than a rerating.